money found for our users $0 and counting. see how it works
claimscout

GLP-1 Receptor Agonist Gastrointestinal Injury Litigation

In litigation Mass-tort payouts ($50k+) mass_tort · pharma

GLP-1 (Ozempic, Mounjaro) gastrointestinal injury MDL 3094 - active intake, bellwether selection underway

Eligibility hint
Took Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and were diagnosed with gastroparesis, severe bowel obstruction, or pancreatitis
Estimated payout range
$50,000 – $1,500,000
MDL filed
2024-02-02
Current score
0.85 / 1.00
Official source
MDL No. 3094 in the Eastern District of Pennsylvania consolidates claims that GLP-1 receptor agonists (semaglutide and tirzepatide) caused gastroparesis, pancreatitis, and bowel obstruction. Sodhi et al. (JAMA, Oct 2023) found about 9x higher pancreatitis rate, 4x bowel obstruction, and 3.7x gastroparesis vs comparator drug. FDA added ileus warning to the Ozempic label in September 2023. MDL covers Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). Bellwether trials anticipated 2027.

Recent signals

Brands: novo nordiskeli lilly
Products: ozempicwegovyrybelsusmounjarozepboundsemaglutidetirzepatideglp-1gastroparesis

Think this might apply to you?
Take a 30-second audit and we'll match every brand you've used against active settlements.

Start audit →
Mass Tort Movers Weekly. 3 velocity calls + 1 deadline. No spam, ever.
Class action settlements pay out via:
🏦Bank transfer
Paper check
PayPal
Venmo
Zelle
💳Prepaid card
Apple Pay
Google Pay
The method is set by the administrator for each settlement, not by claimscout. We never touch the money.